1. Ambrus A., Field E., Gonzalez R. Loss in the time of cholera: long-run impact of a disease epidemic on the urban landscape. Am. Econom. Rev., 2020, vol. 110, no. 2, pp. 475–525. doi: 10.1257/aer.20190759
2. Chan J.F.W., Yuan S., Kok K.H., To K.K.W., Chu H., Yang J., Tsoi H.W. A familial of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 2020. doi: 10.1093/infdis/jiaa077
3. Cucinotta D., Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed., 2020, vol. 91, no. 1, pp. 157–160. doi: 10.23750/abm.v91i1.9397
4. Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial Version 6, Revised). The General Office of National Health Commission 18 February 2020, 13 p.
5. Elfiky A. Sofosbuvir can inhibit the newly emerged coronavirus (2019-nCoV) in Wuhan, China. China (1/20/2020).
6. Guo Y.R., Cao Q.D., Hong Z.S., Tan Y.Y., Chen S.D., Jin H.J., Tan K.S., Wang D.Y., Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak — an update on the status. Military Med. Res., vol. 7, no. 1: 11. doi: 10.1186/s40779-020-00240-0
7. Kon W., Agarwal P.P. Chest imaging appearance of COVID-19 infection. Radiol. Cardiothorac. Imaging, 2020, vol. 2, no. 1: e200028. doi: 10.1148/ryct.2020200028
8. Li H., Wang Y.M., Xu J.Y., Cao B. Potential antiviral therapeutics for 2019 Novel Coronavirus. Zhonghua Jie He He Hu Xi Za Zhi = Chinese Journal of Tuberculosis and Respiratory Diseases, vol. 43, no. 3, pp. 170–172. doi: 10.3760/cma.j.issn.1001-0939.2020.03.004
9. Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y., Xing X. Early transmission dynamics in Wuhan, China, of novel coronavirusinfected pneumonia. N. Engl. J. Med., 2020, no. 382, pp. 1199–1207. doi: 10.1056/NEJMoa2001316
10. Linders D. From e-government to we-government: defining a typology for citizen coproduction in the age of social media. Government Information Quarterly, 2012, vol. 29, no. 4, pp. 446–454. doi: 10.1016/j.giq.2012.06.003
11. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). BioScience Trends, 2020. doi: 10.5582/bst.2020.01020
12. Marmot M. The influence of income on health: views of an epidemiologist. Health Affairs, 2002, vol. 21, no. 2, pp. 31–46.
13. National Healthcare Security Administration. URL: http://www.gov.cn/xinwen/2020-01/30/content_5473177.htm (02.04.2020).
14. ProMED-mail. Pneumonia — China (Guangdong): RFI; ProMED-mail 2003; 10 Feb:2003 20030210.0357.
15. ProMED-mail. Undiagnosed pneumonia — China (HU): RFI. ProMED-mail 2019; 30 Dec:2019 1230.6864153.
16. Rong K., Zhou D., Tang K. We-governance and the block of COVID-2019 27.03.2020. URL: https://ssrn.com/abstract=3560879 (02.04.2020).
17. The novel coronavirus pneumonia emergency response epidemiology team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases COVID-19. China CCDC Weekly, 2020, no. 2, pp. 1–10. URL: http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51 (02.04.2020).
18. Wang Z., Tang K. Combating COVID-19: health equity matters. Nature Med., 2020. doi: 10.1038/s41591-020-0823-6
19. World Health Organization. Pneumonia of unknown cause — China. URL: www.who.int/csr/don/05-january-2020-pneumonia-ofunkown-cause-china/en (02.04.2020).
20. World Health Organization. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). 16–24 February 2020. URL: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf (02.04.2020).
21. World Health Organization. WHO statement regarding cluster of pneumonia cases in Wuhan, China. 9 January 2020. URL: https://www.who.int/china/news/detail/09-01-2020-who-statement-regarding-cluster-of-pneumonia-cases-in-wuhan-china (02.04.2020).
